Pharming Group N.V. (PHAR)

NGM – Real vaqt narxi. Valyuta: USD

13.09

+0.47 (3.69%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Pharming Group Q1 Earnings Call Highlights

Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.

07.05.2026

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

23.04.2026

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a business update on Thursday, May 7, 2026.

16.04.2026

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.com.

07.04.2026

Pharming Group to participate in April investor conferences

Pharming announced that management will participate in investor conferences Needham Virtual Healthcare and Kempen Life Sciences Conferences in April 2026.

02.04.2026

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025.

27.03.2026

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) , a rare primary immunodeficiency Decision based on Phase II/III clinical data demonstrating statistically significant impact on measures of immune dysregulation and immunodeficiency Final European Commission decision expected in Q2 2026 L eiden , the Netherlands, March 27 , 2026 : Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older.

Videolar

No Data

There is no data to display

Press-relizlar

16.04.2026

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.com.

02.04.2026

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

27.03.2026

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

24.03.2026

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS) in adult and pediatric patients aged 4 years and older.

Pharming Group N.V. (PHAR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pharming Group N.V. (PHAR)

Pharming Group Q1 Earnings Call Highlights

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group to participate in April investor conferences

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Videolar

No Data

Press-relizlar

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Pharming Group Q1 Earnings Call Highlights

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group to participate in April investor conferences

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Videolar

No Data

Press-relizlar

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Search stocks

Pharming Group N.V. (PHAR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pharming Group N.V. (PHAR)

Pharming Group Q1 Earnings Call Highlights

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group to participate in April investor conferences

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Videolar

No Data

Press-relizlar

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Pharming Group Q1 Earnings Call Highlights

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group to participate in April investor conferences

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Videolar

No Data

Press-relizlar

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older